Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             255 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection Waegell, W
2002
34 5 p. 1411-1417
artikel
2 A cause of late graft dysfunction after pediatric liver transplantation: de novo autoimmune hepatitis Petz, W
2002
34 5 p. 1958-1959
artikel
3 ACEi-induced attenuation of platelet TIMP-1 production in renal allograft recipients. possible impact on erythropoiesis Lightfoot, B.O
2002
34 5 p. 1806-1807
artikel
4 A cost-effectiveness analysis of tacrolimus versus cyclosporine microemulsion following kidney transplantation Craig, A.-M
2002
34 5 p. 1646-1648
artikel
5 Acute rejection after renal transplantation with tacrolimus-based therapy in conditions of normal clinical practice Scolari, M.P
2002
34 5 p. 1671-1672
artikel
6 Adverse events in renal transplantation under tacrolimus/mycophnolate mofetil immunosuppression: a single-center experience Omoto, K
2002
34 5 p. 1821-1822
artikel
7 Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus Jain, A
2002
34 5 p. 1968-1969
artikel
8 Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients Koefoed-Nielsen, P.B
2002
34 5 p. 1743-1744
artikel
9 Altered PTHrP expression during cold storage with thymoglobulin Hu, M
2002
34 5 p. 1629-1631
artikel
10 Alternative immunosuppression for acute renal failure in liver transplantation: role of ultra–low dose tacrolimus and basiliximab Varo, E
2002
34 5 p. 1533-1534
artikel
11 A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis Stratta, R.J
2002
34 5 p. 1903-1905
artikel
12 Analysis of trends in hospital readmissions and postoperative complications in heart transplant recipients: single center study Donovan, M.P
2002
34 5 p. 1853-1854
artikel
13 Analysis of well-being after organ transplantation in a large cohort of french patients Pageaux, G.P
2002
34 5 p. 1687-1688
artikel
14 Angiotensin II type 1 receptor blockade after cardiac transplantation reduced the incidence and severity of transplant vasculopathy in an animal-based study Richter, M.H.C
2002
34 5 p. 1484-1485
artikel
15 A novel scale of immunosuppression exposure and correlation to outcomes after renal transplantation Morrissey, P.E
2002
34 5 p. 1640-1641
artikel
16 A novel tacrolimus dosing strategy in cardiac transplantation: drug levels, renal function, and biopsy results Baran, D.A
2002
34 5 p. 1834-1835
artikel
17 Antilymphocyte induction is no longer necessary in simultaneous pancreas and kidney transplantation Rigotti, P
2002
34 5 p. 1906-1908
artikel
18 A paired study comparing the efficacy of renal preservation by normothermic autologous blood perfusion and hypothermic pulsatile perfusion Metcalfe, M.S
2002
34 5 p. 1473-1474
artikel
19 A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients Shapiro, R
2002
34 5 p. 1651-1652
artikel
20 A predictive model for chronic allograft nephropathy Cardinal, H
2002
34 5 p. 1810-1811
artikel
21 A randomised trial comparing the efficacy and safety of tacrolimus with microemulsified cyclosporine after liver transplantation Timmermann, W
2002
34 5 p. 1516-1518
artikel
22 A randomized prospective double-blind placebo-controlled study of gallopamil, calcium antagonist of the verapamil type, in stable cyclosporine-treated renal transplant recipients Gossmann, J
2002
34 5 p. 1767-1770
artikel
23 A randomized trial of mycophenolate mofetil versus azathioprine as calcineurin inhibitor sparing agents in the treatment of chronic allograft nephropathy Metcalfe, M.S
2002
34 5 p. 1812-1814
artikel
24 A removable tubing for implanting islet graft and studying immunosuppression Hsu, B.R.-S
2002
34 5 p. 1462
artikel
25 Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults? Troisi, R
2002
34 5 p. 1531-1532
artikel
26 A retrospective analysis of a sirolimus/prograf regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts Youseff, N
2002
34 5 p. 1653-1655
artikel
27 A three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in adult renal transplant recipients Charpentier, B
2002
34 5 p. 1625-1626
artikel
28 Author index 2002
34 5 p. 1979-1984
artikel
29 Azathioprine toxicity and thiopurine methyltransferase genotype in renal transplant patients Pandya, B
2002
34 5 p. 1642-1645
artikel
30 Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results van Hooff, J.P.
2002
34 5 p. 1591-1593
artikel
31 Calcineurin inhibitor–free immunosuppressive regimen for marginal donors/recipients of kidney transplantation Donati, D
2002
34 5 p. 1678-1680
artikel
32 Calcineurin inhibitors are not antagonistic to tolerance induction Cosimi, A.B
2002
34 5 p. 1376-1377
artikel
33 Calcineurin-inhibitor withdrawal in heart transplantation recipients (the case against) Mehra, M.R
2002
34 5 p. 1825-1827
artikel
34 Can acute rejection be prevented in SPK transplantation? Burke, G.W
2002
34 5 p. 1913-1914
artikel
35 Can the immunosupressive effect of perioperative single high-dose antithymocyte globulin administration in kidney allograft recipients be due to apoptosis of activated lymphocytes? Rowiński, W.
2002
34 5 p. 1622-1624
artikel
36 Cardiac allograft vasculopathy: Weis, M
2002
34 5 p. 1847-1849
artikel
37 Cardiovascular risk factors in liver allograft recipients: relationship with immunosuppressive therapy Varo, E
2002
34 5 p. 1553-1554
artikel
38 CD26 expression and enzymatic activity in recipients of kidney allografts Korom, S
2002
34 5 p. 1753-1754
artikel
39 CD62–PSGL-1 interactions regulate cytokine chemokine and apoptotic networks in cardiac allograft recipients Coito, A.J.
2002
34 5 p. 1463-1464
artikel
40 CD25+ regulatory cells generated by intratracheal delivery of alloantigen Akiyama, Y
2002
34 5 p. 1443-1444
artikel
41 CD40 triggered human monocyte-derived dendritic cells convert to tolerogenic dendritic cells when JAK3 activity is inhibited Säemann, M.D
2002
34 5 p. 1407-1408
artikel
42 Changes in renal function in long-term survivors of liver transplantation: a comparison between cyclosporine microemulsion and tacrolimus therapy Charco, R
2002
34 5 p. 1548-1549
artikel
43 Chronic rejection and graft half-life: five-year follow-up of the european tacrolimus multicenter renal study Mayer, A.D
2002
34 5 p. 1491-1492
artikel
44 clinical benefit of monitoring cyclosporine C2 and C4 in long-term liver transplant recipients Barakat, O
2002
34 5 p. 1535-1537
artikel
45 Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients Sifontis, N.M
2002
34 5 p. 1730-1732
artikel
46 Clinical observation on hemophilia a treatment by cadaveric spleen transplantation Xiang, W.Z
2002
34 5 p. 1929-1931
artikel
47 CMV retinitis after renal transplantation Shimakawa, M
2002
34 5 p. 1790-1792
artikel
48 Combined therapy of CTLA4Ig-gene transfection with FTY720 administration in rat lung allografts Kita, Y
2002
34 5 p. 1437-1440
artikel
49 Comparison of tacrolimus and neoral-based immunosuppressive regimens in renal transplantation patients: singles-center experience Gurkan, A
2002
34 5 p. 1661-1662
artikel
50 Comparison of the therapeutic effects between CsA and FK506 on chronic renal allograft injury and TGF-β expression Miyagi, M
2002
34 5 p. 1589-1590
artikel
51 Complete withdrawal of immunosuppression in living donor liver transplantation Oike, F
2002
34 5 p. 1521
artikel
52 Conversion from cyclosporine to tacrolimus is preferred by pediatric renal transplant recipients: a focus on opinions and outcomes Sundberg, A.K
2002
34 5 p. 1951-1952
artikel
53 Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection Chan, M.C.Y
2002
34 5 p. 1850-1852
artikel
54 Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up Citterio, F
2002
34 5 p. 1685-1686
artikel
55 Corticosteroid elimination in renal transplantation: pro Woodle, E.S
2002
34 5 p. 1693
artikel
56 Cyclooxygenase-2 inhibitor induces operational tolerance to fully allogenic cardiac grafts Yokoyama, T
2002
34 5 p. 1405-1406
artikel
57 Cyclophosphamide-induced postoperative anemia in cynomolgus monkey recipients of hdaf-transgenic pig organ xenografts Lam, T.T
2002
34 5 p. 1451-1452
artikel
58 Cyclosporin a does not enhance the development of transplant vasculopathy: experimental study in a rat cardiac transplant model Richter, M.H.C
2002
34 5 p. 1479-1480
artikel
59 Cyclosporine absorption profiling and therapeutic drug monitoring using c2 blood levels in stable renal allograft recipients Einecke, G
2002
34 5 p. 1738-1739
artikel
60 cyclosporine-based quadruple induction therapy versus tacrolimus-based dual immunosuppression after liver transplantation: ten-year follow-up Jonas, S
2002
34 5 p. 1504-1506
artikel
61 Cyclosporine does not influence serum cholesterol in kidney transplant recipients Matzkies, F.K
2002
34 5 p. 1795-1796
artikel
62 Daclizumab and ATG versus ATG in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneus pancreas-kidney transplantation: analysis of early outcome Dette, K
2002
34 5 p. 1909-1910
artikel
63 Delay of hepatitis c recurrence in liver transplant recipients: impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction Fasola, C.G
2002
34 5 p. 1561-1562
artikel
64 De novo breast cancer in renal transplant recipients Buell, J.F
2002
34 5 p. 1778-1779
artikel
65 De novo sarcomas in solid organ transplant recipients Husted, T.L
2002
34 5 p. 1786-1787
artikel
66 15-deoxyspergualin protects the islet graft from macrophage-mediated injury Juang, J.-H
2002
34 5 p. 1458-1459
artikel
67 Design and preliminary results of a randomized study on the conversion of treatment with calcineurin inhibitors to mycophenolate mofetil in chronic renal graft failure: effect, on serum cholesterol levels Suwelack, B
2002
34 5 p. 1803-1805
artikel
68 Diabetes in renal transplant recipients treated with tacrolimus Akioka, K
2002
34 5 p. 1774-1775
artikel
69 Does allopurinol prevent side effects of cyclosporine-A treatment? Kobelt, V
2002
34 5 p. 1425-1427
artikel
70 Donor treatment improves survival of rat cardiac allografts in sensitized recipients Schmidbauer, G.S
2002
34 5 p. 1477-1478
artikel
71 Early experience using calcineurin-free protocol in recipients of high-risk cadaver renal transplants El-Sabrout, R
2002
34 5 p. 1627-1628
artikel
72 Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study Boots, J.M.M
2002
34 5 p. 1698-1699
artikel
73 Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation Böttiger, Y
2002
34 5 p. 1544-1545
artikel
74 Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients Ciancio, G
2002
34 5 p. 1944-1945
artikel
75 Effect of daclizumab, tacrolimus and mycophenolate mofetil in racial minority first renal transplant recipients Ciancio, G
2002
34 5 p. 1617-1618
artikel
76 Effect of immunosuppressive regimen on novel markers of atherothrombosis in heart transplantation: homocysteine, c-reactive protein, and mean platelet volume Mehra, M.R
2002
34 5 p. 1866-1868
artikel
77 Effect of rapamycin in combination with calcineurin inhibitors, FK506 and cyclosporin, following arterial injury Waller, J.R
2002
34 5 p. 1481-1483
artikel
78 Effects of adenoviral vectors containing CTLA4Ig-gene in rat heterotopic lung implants Kita, Y
2002
34 5 p. 1434-1436
artikel
79 Effects of immunosuppressive regimens on plasma levels of transforming growth factor-beta 1 in renal transplant recipients Pozzetto, U
2002
34 5 p. 1740-1742
artikel
80 Efficacy and safety of dual versus triple tacrolimus-based therapy in kidney transplantation: two-year follow-up Garcia, I
2002
34 5 p. 1638-1639
artikel
81 Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: twelve-month follow-up Montagnino, G
2002
34 5 p. 1635-1637
artikel
82 Efficient gene transduction to cultured hepatocytes by HIV-1 derived lentiviral vector Ohashi, K
2002
34 5 p. 1431-1433
artikel
83 Evidence that fasting does not significantly affect trough levels of tacrolimus in stable renal transplant recipients van Duijnhoven, E.M
2002
34 5 p. 1723-1725
artikel
84 Excellent results following 3 years of tacrolimus immunosuppression in kidney transplantation recipients in japan: overall analysis of more than 1000 patients Takahara, S
2002
34 5 p. 1597-1599
artikel
85 Excellent 3-year results following living-donor kidney transplantation and tacrolimus immunosuppression in japan Uchida, K
2002
34 5 p. 1606-1607
artikel
86 Experience with the use of basiliximab in liver transplantation—use in pediatric and adult recipients in combination with cyclosporine or tacrolimus Petz, W
2002
34 5 p. 1966-1967
artikel
87 Expression of high levels of soluble allogeneic major histocompatability complex class i antigen by adenoviral gene transfer strongly inhibits allospecific cytotoxic t lymphocytes in vivo Graeb, C
2002
34 5 p. 1398-1399
artikel
88 Failure of Fas-ligand transgenic islets to resist allogeneic rejection Juang, J.-H
2002
34 5 p. 1456-1457
artikel
89 First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV Langrehr, J.M
2002
34 5 p. 1565-1566
artikel
90 Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantation Budde, K
2002
34 5 p. 1594-1596
artikel
91 FK 506 abrogates induction of regulatory cells after intratracheal delivery of alloantigen Shibutani, S
2002
34 5 p. 1445
artikel
92 FTY720: a novel approach to the treatment of hepatic ischemia-reperfusion injury Anselmo, D.M
2002
34 5 p. 1467-1468
artikel
93 Gastric cancer in transplant recipients: detection of malignacy by aggressive endoscopy Buell, J.F
2002
34 5 p. 1784-1785
artikel
94 Gemcitabine in models of acute and accelerated rejection Jung, F
2002
34 5 p. 1420-1421
artikel
95 Gene expression profiling of acute rejection and mixed lymphocyte reaction with tacrolimus immunosuppression Erickson, L.M
2002
34 5 p. 1385-1386
artikel
96 Heme oxygenase-1 gene transfer prevents CD95/fasl-mediated apoptosis and improves liver allograft survival via carbon monoxide signaling pathway Ke, B
2002
34 5 p. 1465-1466
artikel
97 High level of TGF-β in organ transplantation might be due to rejection rather than calcineurin inhibitor medication Wynn, C
2002
34 5 p. 1387-1389
artikel
98 Histopathological findings according to banff-97 classification system comparing tacrolimus versus cyclosporine Rodrigo, E
2002
34 5 p. 1719-1720
artikel
99 Immunosuppression and merkel cell cancer Buell, J.F
2002
34 5 p. 1780-1781
artikel
100 Immunosuppression and the prognosis of patients suffering from myeloproliferative disorders after liver transplantation Bahr, M.J
2002
34 5 p. 1493-1494
artikel
101 Immunosuppression in cadaveric renal transplant recipients from non–heart-beating donors in a single center Ushigome, H
2002
34 5 p. 1681-1682
artikel
102 Immunosuppression in cadaveric renal transplant recipients from non–heart-beating donors in a single center Ushigome, H
2002
34 5 p. 1503
artikel
103 Immunosuppressive management following small bowel transplantation Mueller, A.R
2002
34 5 p. 1894-1896
artikel
104 Immunosuppressive regimen in lung transplantation: initial intravenous mycophenolate mofetil and cyclosporine avoid cytolytic induction and allow for rapid steroid tapering Fieguth, H.G
2002
34 5 p. 1879-1880
artikel
105 Immunosupressive agents and their actions First, M.R
2002
34 5 p. 1369-1371
artikel
106 Impact of ACE polymorphism on renal allograft function, blood pressure, and proteinuria under ACE inhibition Suwelack, B
2002
34 5 p. 1763-1766
artikel
107 Impact of HLA matching upon outcome after liver transplantation Neumann, U.P
2002
34 5 p. 1499-1500
artikel
108 Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients Boucher, A
2002
34 5 p. 1799-1802
artikel
109 Impact of noncompliance and donor/recipient race matching on chronic liver rejection Haustein, S.V
2002
34 5 p. 1497-1498
artikel
110 Improved lipid profile and blood sugar control in pediatric renal transplant recipients using sirolimus-tacrolimus combination El-Sabrout, R
2002
34 5 p. 1946-1947
artikel
111 Improved outcome of minor-mismatched living renal allografts under tacrolimus immunosuppression Tanabe, K
2002
34 5 p. 1668-1670
artikel
112 Improvement of cardiovascular risk factors in heart transplant recipients after conversion from cyclosporine to tacrolimus: a role of the TGF-β system van Riemsdijk, I.C
2002
34 5 p. 1864-1865
artikel
113 Improving results in solitary pancreas transplantation with portal-enteric drainage and thymoglobulin induction Stratta, R.J
2002
34 5 p. 1915-1917
artikel
114 Incidence of cytomegalovirus infection and disease in orthotopic liver transplant patients immunosuppressed with cyclosporin versus tacrolimus Varo, E
2002
34 5 p. 1567-1568
artikel
115 Incidence of cytomegalovirus infections after immunosuppression induction in clinical islet transplantation and impact on graft function Eckhard, M
2002
34 5 p. 1922-1924
artikel
116 Increased acute rejection episodes among recipients of living unrelated donor compared with cadaver and living related donor renal transplants Long, D.G
2002
34 5 p. 1673-1674
artikel
117 Increased frequency of lymphoceles under treatment with sirolimus following renal transplantation: a single center experience Giessing, M
2002
34 5 p. 1815-1816
artikel
118 Induction of prolonged survival of fully allogeneic cardiac graft by intratracheal delivery of a single major histocompatability complex class i peptide Akiyama, Y
2002
34 5 p. 1396-1397
artikel
119 Induction therapy for adult small bowel transplant with Campath-1H Nishida, S
2002
34 5 p. 1889-1891
artikel
120 Induction therapy for small bowel transplant recipients: early experience in Birmingham, UK Beath, S.V
2002
34 5 p. 1892-1893
artikel
121 Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids Asensio, M
2002
34 5 p. 1970-1971
artikel
122 Influence of antihypertensive drugs on renal microcirculation and renal hemodynamics in cyclosporine a-treated rats Hillebrand, U
2002
34 5 p. 1383-1384
artikel
123 Influence of immunoprophylaxis on renal graft function and survival Woodside, K.J
2002
34 5 p. 1619-1621
artikel
124 Influence of immunosuppressive drugs on intestinal epithelial transport function Stockmann, M
2002
34 5 p. 1449-1450
artikel
125 Inhibition of epithelial replacement by nonspecific immunosuppressants accelerates rat orthotopic tracheal allograft rejection Ito, Y
2002
34 5 p. 1441-1442
artikel
126 Inhibition of IL-12 signaling stat4/IFN-γ pathway by rapamycin is associated with impaired dendritc cell function Chiang, P.-H
2002
34 5 p. 1394-1395
artikel
127 Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus–positive liver and kidney transplantation patients Jain, A.K.B
2002
34 5 p. 1540-1541
artikel
128 Intestinal transplantation in children: Paris experience Goulet, O
2002
34 5 p. 1887-1888
artikel
129 Intestinal transplantation including the colon in children Goulet, O
2002
34 5 p. 1885-1886
artikel
130 Intravenous administration of antithrombin III induces indefinite survival of fully allogeneic cardiac grafts Aramaki, O
2002
34 5 p. 1409-1410
artikel
131 In vivo test of two low doses of mycophenolate mofetil in an experimental model of islet allotransplantation Xekouki, P
2002
34 5 p. 1446-1448
artikel
132 Is immunosuppression justified for nonuremic diabetic patients to keep them insulin independent? (The argument for) Sutherland, D.E.R.
2002
34 5 p. 1927-1928
artikel
133 Islet cell transplantation: should we use more than one pancreas? Con Burke, G.W
2002
34 5 p. 1925-1926
artikel
134 Is there a need for surveillance endomyocardial biopsies inheart transplantation? Kirklin, J.K
2002
34 5 p. 1857-1859
artikel
135 Lectin staining for urine cytologic monitoring after kidney transplantation Grupp, C
2002
34 5 p. 1751-1752
artikel
136 Lipid profiles after liver transplantation in patients receiving tacrolimus or cyclosporin Aguirrezabalaga, J
2002
34 5 p. 1551-1552
artikel
137 Liver transplantation across ABO blood groups Lang, M
2002
34 5 p. 1501-1502
artikel
138 Liver transplantation in infants: how much immunosuppression is needed? Ganschow, R
2002
34 5 p. 1963
artikel
139 Liver transplantation in infants younger than 6 months old Grabhorn, E
2002
34 5 p. 1964-1965
artikel
140 Liver transplant induction trial of daclizumab to spare calcineurin inhibition Heffron, T.G
2002
34 5 p. 1514-1515
artikel
141 Local immunosuppression with kidney-targeting prednisolone prodrug prolong rat renal allograft survival Su, M
2002
34 5 p. 1422-1424
artikel
142 Long-term graft acceptance after rat liver allograft transplantation induced by application of CTLA4-Ig and donor specific spleen cell administration Neumann, U.P
2002
34 5 p. 1400-1401
artikel
143 Long-term outcome of tacrolimus in cadaveric kidney transplantation from non–heart-beating donors Fukuhara, N.
2002
34 5 p. 1577-1579
artikel
144 Long-term results and complications of living related kidney transplantation in a single center Yoshimura, N
2002
34 5 p. 1675-1677
artikel
145 Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil Sola, E
2002
34 5 p. 1689-1690
artikel
146 Low-dose tacrolimus, trough-monitored mycophenolate mofetil, and planned steroid withdrawal for cadaveric kidney transplantation: a single center experience Beaunoyer, M
2002
34 5 p. 1694-1695
artikel
147 Low incidence of graft arteriosclerosis after cardiac transplantation: risk factor analysis for patients with induction therapy Zuckermann, A.
2002
34 5 p. 1869-1871
artikel
148 Low incidence of hypercholesterolemia among liver transplant patients under tacrolimus monotherapy immunosuppression Charco, R
2002
34 5 p. 1555-1556
artikel
149 Low incidence of posttransplant lymphoproliferative disease in children treated with low-dose immunosuppression after liver transplantation Ganschow, R
2002
34 5 p. 1961-1962
artikel
150 Macrophage blockade induced by repeated gadolinium chloride injections saves human fetal islet xenografting in rats Farkas, G
2002
34 5 p. 1460-1461
artikel
151 Malignancy in organ transplantation: Hunt, S.A
2002
34 5 p. 1874-1876
artikel
152 Medium-term outcome using sirolimus-tacrolimus combination in adult renal transplant recipients Rashid, I
2002
34 5 p. 1649-1650
artikel
153 Microarray analysis of gene expression in peripheral blood mononuclear cells derived from long-surviving renal recipients Zhang, H.Q
2002
34 5 p. 1757-1759
artikel
154 Microchimerism in patients after orthotopic liver transplantation: a prognostic indicator? Junge, G
2002
34 5 p. 1542-1543
artikel
155 Monoterpene geraniol prevents acute allograft rejection Ji, P
2002
34 5 p. 1418-1419
artikel
156 Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients Lietz, K
2002
34 5 p. 1828-1829
artikel
157 Mycophenolate mofetil reduces late renal allograft loss: a 4-year study Nghiem, D.D
2002
34 5 p. 1683-1684
artikel
158 Mycophenolate mofetil without antibody induction in pediatric renal transplantation Ojogho, O
2002
34 5 p. 1953-1954
artikel
159 Mycophenolate’s influence in the treatment of recurrent hepatitis c following liver transplantation Smallwood, G.A
2002
34 5 p. 1559-1560
artikel
160 Noncompliance postrenal transplantation: measuring the extent of the problem using electronic surveillance and nurse practitioner interviews Hardstaff, R
2002
34 5 p. 1608-1609
artikel
161 One year evolution of bone mineral density in kidney transplant recipients receiving tacrolimus versus cyclosporine El Haggan, W
2002
34 5 p. 1817-1818
artikel
162 One-year follow-up of a brazilian randomized multicenter study comparing tacrolimus versus cyclosporine in kidney transplantation Campos, H.H
2002
34 5 p. 1656-1658
artikel
163 One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion Filler, G
2002
34 5 p. 1935-1938
artikel
164 Optimal use of tacrolimus in living donor renal transplantation in children Hasegawa, A
2002
34 5 p. 1939-1941
artikel
165 Oral dosing of tacrolimus and cyclosporine microemulsion—results from a large multicenter study in renal transplantation Dietl, K.-H
2002
34 5 p. 1659-1660
artikel
166 Osteoporosis screening in an outpatient liver transplant clinic: impact of primary immunosuppression Smallwood, G.A
2002
34 5 p. 1569-1570
artikel
167 Outcome of kidney transplantation from non–heart-beating donors followed by tacrolimus immunosuppression in japan Tanabe, K
2002
34 5 p. 1580-1582
artikel
168 Pancreas transplantation in cross-match-positive recipients using cyclosporine- or tacrolimus-based immunosuppression Khwaja, K
2002
34 5 p. 1901-1902
artikel
169 Patient profile and candidacy for intestinal transplantation at the University of Pittsburgh Martin, D
2002
34 5 p. 1897-1898
artikel
170 Patients with high cholesterol levels benefit most from early withdrawal of corticosteroids Rigotti, P
2002
34 5 p. 1797-1798
artikel
171 Patterns and outcomes for maintenance immunosuppression in the UNOS renal transplant registry Takemoto, S.K
2002
34 5 p. 1632-1634
artikel
172 Pediatric liver transplantation in 808 consecutive children: 20-years experience from a single center Jain, A
2002
34 5 p. 1955-1957
artikel
173 Peripheral lymphocyte subsets in the management of PTLD Gupte, G.L
2002
34 5 p. 1782-1783
artikel
174 Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients Budde, K
2002
34 5 p. 1748-1750
artikel
175 Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus Sindhi, R
2002
34 5 p. 1960
artikel
176 Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy Braun, K.-P
2002
34 5 p. 1745-1747
artikel
177 Pharmacokinetics of tacrolimus in heart transplantation Undre, N.A
2002
34 5 p. 1836-1838
artikel
178 Pharmacokinetics of tacrolimus in paediatric renal transplant recipients Webb, N.J.A
2002
34 5 p. 1948-1950
artikel
179 Pirfenidone inhibits early neointimal proliferation following arterial injury Waller, J.R.
2002
34 5 p. 1486-1488
artikel
180 Polyomavirus in kidney and kidney–pancreas transplantation: a defined protocol for immunosuppression reduction and histologic monitoring Trofe, J
2002
34 5 p. 1788-1789
artikel
181 Poor graft survival in patients historically positive for antidonor antibody after living related renal transplantations Nanri, M
2002
34 5 p. 1583
artikel
182 Posttransplant diabetes mellitus after orthotopic liver transplantation Stockmann, M
2002
34 5 p. 1571-1572
artikel
183 Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus Baran, D.A
2002
34 5 p. 1872-1873
artikel
184 Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match Sonnenday, C.J
2002
34 5 p. 1614-1616
artikel
185 Preface Busuttil, Ronald W
2002
34 5 p. 1365
artikel
186 Pregnancy outcomes in female heart and heart-lung transplant recipients Cowan, S.W
2002
34 5 p. 1855-1856
artikel
187 Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants Sindhi, R
2002
34 5 p. 1972-1973
artikel
188 Primary immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared with neoral therapy Waller, J.R
2002
34 5 p. 1587-1588
artikel
189 Prospective analysis of thrombotic microangiopathy after renal transplantation: comparison between cyclosporine and tacrolimus immunosuppression Tanabe, K
2002
34 5 p. 1819-1820
artikel
190 Prospective randomized pilot study of steroid withdrawal with mycophenolate mofetil in long-term cyclosporine-treated patients: 4-year follow-up Budde, K
2002
34 5 p. 1703-1706
artikel
191 Prospective study of a tacrolimus-based quadruple immunosuppressive regimen: evaluation of safety and efficacy Lladó, L
2002
34 5 p. 1526-1528
artikel
192 Randomized conversion from cyclosporine to tacrolimus in renal transplant patients: improved lipid profile and unchanged plasma homocysteine levels Artz, M.A
2002
34 5 p. 1793-1794
artikel
193 Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection Burke, G.W
2002
34 5 p. 1610-1611
artikel
194 Rapamycin blocks the generation of regulatory t cells facilitated by posttransplant infusion of donor t cells through increasing the apoptosis of thymic CD4+CD25+ cells Tsui, T.-Y
2002
34 5 p. 1390-1391
artikel
195 Recurrence of hepatitis c in liver transplant recipients treated with mycophenolate mofetil Fasola, C.G
2002
34 5 p. 1563-1564
artikel
196 Regulatory t cells induced by allochimeric major histocompatability class i therapy inhibit allograft apoptosis Semiletova, N
2002
34 5 p. 1402
artikel
197 Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients El-Sabrout, R
2002
34 5 p. 1942-1943
artikel
198 Renal sparing effects of mycophenolate when used in long-term liver transplant receipients Smallwood, G.A
2002
34 5 p. 1550
artikel
199 Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels Suwelack, B
2002
34 5 p. 1808-1809
artikel
200 Requirement of the costimulatory signal in xeno-MHC-restricted helper T-cell activation Iwata, H
2002
34 5 p. 1453-1455
artikel
201 Risk-directed immunosuppression in heart transplant recipients: maintenance prednisone can be avoided in selected patients Arnold, A.N
2002
34 5 p. 1830-1833
artikel
202 Risk of adrenal insufficiency with steroid maintenance therapy in renal transplantation Boots, J.M.M
2002
34 5 p. 1696-1697
artikel
203 Safety analysis following tacrolimus immunosuppression in renal transplant recipients in Japan: 3-year results in over 1000 patients Yoshimura, N
2002
34 5 p. 1600-1603
artikel
204 Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study Squifflet, J.-P
2002
34 5 p. 1584-1586
artikel
205 Should priority on the waiting list be given to patients with diabetes: pro Gruessner, R.W.G
2002
34 5 p. 1575-1576
artikel
206 Sialyl lewisx monitoring as an early detector of b-cell-dependent rejection Ishida, H
2002
34 5 p. 1760-1762
artikel
207 Sirolimus and tacrolimus in clinical cardiac transplantation Pham, S.M
2002
34 5 p. 1839-1842
artikel
208 Sirolimus-based immunosuppresive protocol for calcineurin sparing in liver transplantation Heffron, T.G
2002
34 5 p. 1522-1523
artikel
209 Sirolimus-based steroid-free maintenance immunosuppression Mital, D
2002
34 5 p. 1709-1710
artikel
210 Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth Schumacher, G
2002
34 5 p. 1392-1393
artikel
211 Stem cells and their clinical application Domínguez-Bendala, J
2002
34 5 p. 1372-1375
artikel
212 Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients Figueras, J
2002
34 5 p. 1511-1513
artikel
213 Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen Burke III, G.W
2002
34 5 p. 1918-1919
artikel
214 Steroids may compromise quality of life of renal transplant recipients on a tacrolimus-based regimen Moons, P
2002
34 5 p. 1691-1692
artikel
215 Steroid weaning in heart transplantation is associated with decreased b-type natriuretic peptide: Uber, P.A
2002
34 5 p. 1843-1844
artikel
216 Steroid withdrawal from tacrolimus-based therapy in renal transplant patients Citterio, F
2002
34 5 p. 1707-1708
artikel
217 Steroid withdrawal under tacrolimus for primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis after liver transplantation and long-term survival Jain, A
2002
34 5 p. 1524-1525
artikel
218 Study of pharmacokinetic parameters of tacrolimus by different oral administration periods in renal transplantation Saito, K
2002
34 5 p. 1726-1729
artikel
219 Successful results after 3 years’ tacrolimus immunosuppression in abo-incompatible kidney transplantation recipients in japan Takahashi, K
2002
34 5 p. 1604-1605
artikel
220 Successful steroid withdrawal at the end of the 1st year after renal transplantion in mycophenolate mofetil-treated patients Budde, K
2002
34 5 p. 1700-1702
artikel
221 Surveillance biopsies in heart and lung transplantation Hummel, M
2002
34 5 p. 1860-1863
artikel
222 Synergistic effect of high-dose mizoribine and low-dose tacrolimus on renal allograft survival in nonhuman primates Tanabe, K
2002
34 5 p. 1428
artikel
223 Tacrolimus and cardiac transplantation: Baran, D.A
2002
34 5 p. 1845-1846
artikel
224 Tacrolimus and new onset diabetes mellitus: the effect of steroid weaning Baran, D.A
2002
34 5 p. 1711-1712
artikel
225 Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: role of hepatitis c infection Baid, S
2002
34 5 p. 1771-1773
artikel
226 Tacrolimus-based immunosuppression in renal transplantation: 78 experiences in a single japanese center Okamoto, M
2002
34 5 p. 1666-1667
artikel
227 Tacrolimus for treatment of bronchiolitis obliterans syndrome after unilateral and bilateral lung transplantation Fieguth, H.G
2002
34 5 p. 1884
artikel
228 Tacrolimus inhibits platelet-derived growth factor ligand and receptor induction as well as rejection changes in rat renal allografts during long-term follow-up Savikko, J
2002
34 5 p. 1382
artikel
229 Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients Rabkin, J.M
2002
34 5 p. 1557-1558
artikel
230 Tacrolimus is effective in both dual and triple regimens after liver transplantation Serrano, J
2002
34 5 p. 1529-1530
artikel
231 Tacrolimus monotherapy in renal transplantation: four-year data Coupes, B.M
2002
34 5 p. 1612-1613
artikel
232 Tacrolimus/mycophenolate mofetil vs cyclosporine A/Azathioprine after simultaneous pancreas and kidney transplantation: five-year results of a randomized study Woeste, G
2002
34 5 p. 1920-1921
artikel
233 Tacrolimus treats ongoing allograft rejection by inhibiting interleukin-10 mediated functional cytotoxic cell infiltration Ebbs, A
2002
34 5 p. 1378-1381
artikel
234 Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients Toda, F
2002
34 5 p. 1733-1735
artikel
235 Tacrolimus versus cyclosporine in primary simultaneous pancreas-kidney transplantation: preliminary results at 1 year of a large multicenter trial Land, W
2002
34 5 p. 1911-1912
artikel
236 Targeting the ERK-1/2 signalling pathway results in alloantigen-specific anergy in human t cells Krieger, P.-M
2002
34 5 p. 1403-1404
artikel
237 Ten-year results of a randomised prospective study of FK506 versus cyclosporine in management of primary orthotopic liver transplantation Chen, J.W.C
2002
34 5 p. 1507-1510
artikel
238 The case against less rejection with portal venous drainage and pancreas transplantation Henry, M.L
2002
34 5 p. 1899-1900
artikel
239 The case against protocol kidney biopsies Ponticelli, C
2002
34 5 p. 1716-1718
artikel
240 The case for protocol kidney biopsies Isoniemi, H
2002
34 5 p. 1713-1715
artikel
241 The choice of calcineurin inhibitor does not influence centrilobular necrosis after orthotopic liver transplantation Hassoun, Z
2002
34 5 p. 1519-1520
artikel
242 The effect of evening administration of prednisolone on postrenal transplant diabetes mellitus patients Amada, N
2002
34 5 p. 1776-1777
artikel
243 The impact of donor factors on the outcomes following liver transplantation Buell, J.F
2002
34 5 p. 1495-1496
artikel
244 The number of peripheral CD4CD25 cells and early postoperative episodes in renal transplantation Satoh, S
2002
34 5 p. 1755-1756
artikel
245 Therapeutic drug monitoring of tacrolimus early after liver transplantation Braun, F
2002
34 5 p. 1538-1539
artikel
246 The role of tissue factor in renal ischemic reperfusion injury by antisense oligodeoxynucleotide Matsuyama, M
2002
34 5 p. 1475-1476
artikel
247 Thirteen years’ experience in pediatric liver transplantation: differences between tacrolimus and cyclosporine Zajicek, A
2002
34 5 p. 1976-1978
artikel
248 Tolerance induction following orthotopic rat liver transplantation: cytokine production by CD4+ t cells determines the immunological response Gassel, H.-J
2002
34 5 p. 1429-1430
artikel
249 Two-hour blood tacrolimus levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal transplant patients Jørgensen, K.A
2002
34 5 p. 1721-1722
artikel
250 Two-year outcome in renal allograft recipients comparing neoral-led with tacrolimus-led therapy Wayman, M.R
2002
34 5 p. 1663-1665
artikel
251 Usefulness of cooling perfusion apparatus in cadaveric kidney perfusion Hattori, R
2002
34 5 p. 1469-1472
artikel
252 Usefulness of monitoring of AUC0–4h during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation Uchida, K
2002
34 5 p. 1736-1737
artikel
253 Use of calcineurin inhibitors in pediatric liver transplantation: a single-center experience Taylor, R.M
2002
34 5 p. 1974-1975
artikel
254 Use of mycophenolate mofetil in liver transplant recipients experiencing renal dysfunction on cyclosporine or tacrolimus—randomized, prospective, multicenter study results Hodge, E.E
2002
34 5 p. 1546-1547
artikel
255 Value of mycophenolic acid trough level monitoring after lung transplantation Devyatko, E
2002
34 5 p. 1881-1883
artikel
                             255 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland